Live feed07:30:00·548dPRReleasevia QuantisnowXOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its PortfolioByQuantisnow·Wall Street's wire, on your screen.XOMA· XOMA Royalty CorporationHealth Care
